DXCM (DexCom) Marketable Securities: $1,297 Mil (As of Mar. 2026)


DXCM DexCom Inc DXCM
94 GF Score
Price $72.57
GF Value $103.96
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is DexCom Marketable Securities?

DexCom DXCM +1.85% 94 Marketable Securities is $1,297 Mil as of Mar. 2026. GuruFocus rates DXCM with a GF Score™ of 94/100 and a GF Value™ of $103.96 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. DexCom's Marketable Securities for the quarter that ended in Mar. 2026 was $1,297 Mil.

DexCom's annual Marketable Securities declined from Dec. 2023 ($2,158 Mil) to Dec. 2024 ($1,973 Mil) and declined from Dec. 2024 ($1,973 Mil) to Dec. 2025 ($1,081 Mil).

DexCom  (NAS:DXCM) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

DexCom Marketable Securities Related Terms

DexCom Marketable Securities Historical Data

* Premium members only.

The historical data trend for DexCom's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexCom Marketable Securities Chart

DexCom Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,678.60 1,813.90 2,157.80 1,973.30 1,081.00

DexCom Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,796.50 1,770.30 1,486.40 1,081.00 1,297.00
DXCM
94GF Score
DexCom Inc DXCM
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexCom Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $1,297 Mil mean?
DexCom (DXCM) has a Marketable Securities of $1,297 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on DexCom and its competitors.
Is DexCom's Marketable Securities too high?
DexCom's current Marketable Securities is $1,297 Mil. Overall, DexCom has a GF Score™ of 94/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DexCom's Marketable Securities compare to GEHC and STE?
DexCom's Marketable Securities of $1,297 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Devices & Instruments company?
A good Marketable Securities depends on the Medical Devices & Instruments industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on DexCom and its competitors. DexCom's current Marketable Securities is $1,297 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexCom stock overvalued right now?
Based on GuruFocus' analysis, DexCom (DXCM) is currently considered Significantly Undervalued. The stock's GF Value™ is $103.96, compared to a current price of $72.57 — trading 30.2% below its estimated fair value. The current Marketable Securities is $1,297 Mil. DexCom's overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For DexCom (DXCM), the current Marketable Securities is $1,297 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DexCom (DXCM) Overvalued in 2026?

Based on GuruFocus' analysis, DexCom stock appears to be undervalued. The current stock price of $72.57 is trading 30.2% below its estimated GF Value™ of $103.96. GuruFocus considers DexCom to be Significantly Undervalued.

Key valuation signals for DXCM:

  • Marketable Securities: $1,297 Mil
  • GF Value™: $103.96 vs. price of $72.57 (30.2% below fair value)
  • GF Score™: 94/100 with 3 warning signs

No single metric tells the full story. See the DXCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DexCom Business Description

Address 6340 Sequence Drive, San Diego, CA, USA, 92121
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
94GF Score

Get the complete analysis for DXCM

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$72.57
Price
$103.96
GF Value